Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
Hospital Universitario 12 De Octubre · Hematology Oncology Consultants · +19 more institutions
Abstract
•Durvalumab plus EP showed sustained OS benefit over EP with a well-tolerated safety profile after median follow-up >3 years.•Three times more patients were estimated to be alive at 3 years when treated with durvalumab plus EP versus EP alone.•These results further establish durvalumab plus EP as standard of care for first-line treatment of patients with ES-SCLC. BackgroundIn the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC). Durvalumab plus tremelimumab plus EP numerically improved OS versus EP, but did not reach statistical…
Citation impact
- FWCI
- 28.91
- Percentile
- 100%
- References
- 18
Authors
21Topics & keywords
- Durvalumab
- Tremelimumab
- Medicine
- Hazard ratio
- Internal medicine
- Confidence interval
- Urology
- Oncology
- Good health and well-being
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- MMerck
- NNovartis
- RRoche
- SSanofi
- CCelgene
- FHF. Hoffmann-La Roche
- MSMeso Scale Diagnostics
- BIBoehringer Ingelheim
- TPTakeda Pharmaceutical Company
- JPJazz Pharmaceuticals
- AEAstraZeneca España
- DDaiichi-Sankyo
- SServier
- IIpsen
- GGenentech
- JPJanssen Pharmaceuticals